表紙：静脈疾患治療の世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

市場調査レポート

商品コード

1121709

静脈疾患治療の世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Venous Diseases Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts, 2022-2031

出版日: 2022年07月19日 | 発行: Transparency Market Research

| ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 5,795 908,424円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Multi-user License)

USD 8,795 1,378,704円

レポートPDFを同一の部署内・課内の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Corporate License)

USD 11,795 1,848,984円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の静脈疾患治療市場について調査分析し、市場動向、セグメント分析、地域分析、企業プロファイルなどを提供しています。

イントロダクション
- 主要な調査結果
市場の価値予測（2017年～2031年）：治療タイプ別
- 手術
- セラピー
市場の価値予測（2017年～2031年）：疾患タイプ別
- 深部静脈血栓性静脈炎
- 静脈瘤
- 表在性血栓性静脈炎
- 慢性静脈不全
- 静脈性潰瘍
- その他
市場の価値予測（2017年～2031年）：製品タイプ別
- アブレーション装置
- 静脈ステント
- 静脈閉鎖治療
- 硬化療法注射
- その他
市場の価値予測（2017年～2031年）：エンドユーザー別
- 病院
- 診療所
- 外来センター
市場の価値予測（2017年～2031年）：国別/地域別
- 米国
- カナダ
市場の魅力分析
- 治療タイプ別
- 疾患タイプ別
- 製品タイプ別
- エンドユーザー別
- 国別/地域別

第12章欧州の静脈疾患治療の分析と予測

第13章アジア太平洋の静脈疾患治療の分析と予測

第14章ラテンアメリカの静脈疾患治療の分析と予測

第15章中東・アフリカの静脈疾患治療の分析と予測

第16章競合情勢

市場企業 - 競合マトリクス（階層・企業規模別）
市場シェア分析（2021年）：企業別
企業プロファイル
- Zimmer Biomet Holdings, Inc.
- Medtronic
- AngioDynamics
- Alma Lasers
- Biolitec AG Untere Viaduktgasse
- Becton, Dickinson and Company
- Boston Scientific Corporation
- Abbott Laboratories
- B. Braun Melsungen AG
- Teleflex Incorporated
- Lumenis
- Philips

図表

List of Tables

Table 01: Global Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 02: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
Table 03: Global Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
Table 04: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
Table 05: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Region, 2017-2031
Table 06: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by Country, 2017-2031
Table 07: North America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 08: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
Table 09: North America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
Table 10: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
Table 11: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 13: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
Table 14: Europe Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
Table 15: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
Table 16: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 18: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
Table 19: Asia Pacific Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
Table 20: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
Table 21: India Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 22: India Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
Table 23: India Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
Table 24: India Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
Table 25: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 26: Latin America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 27: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
Table 28: Latin America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
Table 29: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
Table 30: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 31: Middle East & Africa Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 32: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
Table 33: Middle East & Africa Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
Table 34: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031

List of Figures

Figure 01: Global Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 02: Global Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 03: Global Venous Diseases Treatment Revenue (US$ Bn), by Surgeries, 2017-2031
Figure 04: Global Venous Diseases Treatment Revenue (US$ Bn), by Therapies, 2017-2031
Figure 05: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
Figure 06: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Product Type, 2017-2031
Figure 07: Global Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
Figure 08: Global Venous Diseases Treatment Attractiveness Analysis, by Angioplasty or Stenting, 2022-2031
Figure 09: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Vein Ligation and stripping, 2017-2031
Figure 10: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Vena Cava Filter, 2017-2031
Figure 11: Global Venous Diseases Treatment Value Share Analysis, by Ambulatory Phlebectomy Type, 2021 and 2031
Figure 12: Global Venous Diseases Treatment Attractiveness Analysis, by Others, 2022-2031
Figure 13: Global Venous Diseases Treatment Revenue (US$ Bn), by Sclerotherapy, 2017-2031
Figure 14: Global Venous Diseases Treatment Revenue (US$ Bn), by Laser treatment, 2017-2031
Figure 15: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Radiofrequency ablation therapy, 2017-2031
Figure 16: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Varicose Veins 2017-2031
Figure 17: Global Venous Diseases Treatment Value Share Analysis, by Superficial Thrombophlebitis, 2021 and 2031
Figure 18: Global Venous Diseases Treatment Attractiveness Analysis, by Deep-vein Thrombophlebitis, 2022-2031
Figure 19: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Chronic Venous Insufficiency, 2017-2031
Figure 20: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Venous ulcers, 2017-2031
Figure 21: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Others, 2017-2031
Figure 22: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Ablation Devices, 2017-2031
Figure 23: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Sclerotherapy Injection, 2017-2031
Figure 24: Global Venous Diseases Treatment Attractiveness Analysis, by Venous Closure Treatments, 2022-2031
Figure 25: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Venous stents
Figure 26: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Others, 2017-2031
Figure 27: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Hospitals, 2017-2031
Figure 28: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Clinics, 2017-2031
Figure 29: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Ambulatory centers, 2017-2031
Figure 30: Global Venous Diseases Treatment Value Share Analysis, by Region, 2021 and 2031
Figure 31: Global Venous Diseases Treatment Attractiveness Analysis, by Region, 2022-2031
Figure 32: North America Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
Figure 33: North America Venous Diseases Treatment Value Share Analysis, by Country, 2021 and 2031
Figure 34: North America Venous Diseases Treatment Attractiveness Analysis, by Country, 2022-2031
Figure 35: North America Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 36: North America Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 37: North America Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
Figure 38: North America Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
Figure 39: North America Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
Figure 40: North America Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
Figure 41: North America Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
Figure 36: North America Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
Figure 37: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
Figure 38: Europe Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 39: Europe Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 40: Europe Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 41: Europe Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 42: Europe Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
Figure 43: Europe Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
Figure 44: Europe Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
Figure 45: Europe Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
Figure 46: Europe Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
Figure 47: Europe Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
Figure 48: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
Figure 49: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 50: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 51: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 52: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 53: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
Figure 54: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
Figure 55: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
Figure 56: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
Figure 57: Asia Pacific Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
Figure 58: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
Figure 59: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
Figure 60: Latin America Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 61: Latin America Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 62: Latin America Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 63: Latin America Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 64: Latin America Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
Figure 65: Latin America Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
Figure 66: Latin America Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
Figure 67: Latin America Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
Figure 68: Latin America Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
Figure 69: Latin America Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
Figure 70: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
Figure 71: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 72: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 73: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 74: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 75: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
Figure 76: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
Figure 77: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
Figure 78: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
Figure 79: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
Figure 80: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
Figure 81: Company Market Share Analysis, 2021

Product Code: TMRGL84870

The report provides revenue of the global venous diseases treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global venous diseases treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the venous diseases treatment market.

The report delves into the competitive landscape of the global venous diseases treatment market. Key players operating in the global venous diseases treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global venous diseases treatment market profiled in this report.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Venous Diseases Treatment Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Porter's Five Force Analysis

5. Key Insights

5.1. Regulatory Scenario by Region/globally
5.2. Technological Advancements
5.3. Pipeline Analysis
5.4. Key Mergers & Acquisitions
5.5. Disease Prevalence & Incidence Rate globally with key countries
5.6. Reimbursement Scenario by Region/globally

6. Global Venous Diseases Treatment Analysis and Forecast, by Treatment Type

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017-2031
- 6.3.1. Surgeries
  - 6.3.1.1. Angioplasty or Stenting
  - 6.3.1.2. Vein Ligation and Stripping
  - 6.3.1.3. Vena Cava Filter
  - 6.3.1.4. Ambulatory Phlebectomy
  - 6.3.1.5. Others
- 6.3.2. Therapies
  - 6.3.2.1. Sclerotherapy
  - 6.3.2.2. Radiofrequency Ablation Therapy
  - 6.3.2.3. Laser Treatment
6.4. Market Attractiveness Analysis, by Treatment

7. Global Venous Diseases Treatment Analysis and Forecast, by Disease Type

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease Type, 2017-2031
- 7.3.1. Deep-vein Thrombophlebitis
- 7.3.2. Varicose Veins
- 7.3.3. Superficial Thrombophlebitis
- 7.3.4. Chronic Venous Insufficiency
- 7.3.5. Venous Ulcers
- 7.3.6. Others
7.4. Market Attractiveness Analysis, by Disease Type

8. Global Venous Diseases Treatment Analysis and Forecast, by Product Type

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Product Type, 2017-2031
- 8.3.1. Ablation Devices
- 8.3.2. Venous Stents
- 8.3.3. Venous Closure Treatments
- 8.3.4. Sclerotherapy Injection
- 8.3.5. Others
8.4. Market Attractiveness Analysis, by Product Type

9. Global Venous Diseases Treatment Analysis and Forecast, by End-user

9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017-2031
- 9.3.1. Hospitals
- 9.3.2. Clinics
- 9.3.3. Ambulatory centers
9.4. Market Attractiveness Analysis, by End-user

10. Global Venous Diseases Treatment Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region

11. North America Venous Diseases Treatment Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017-2031
- 11.2.1. Surgeries
  - 11.2.1.1. Angioplasty or Stenting
  - 11.2.1.2. Vein Ligation and Stripping
  - 11.2.1.3. Vena Cava Filter
  - 11.2.1.4. Ambulatory Phlebectomy
  - 11.2.1.5. Others
- 11.2.2. Therapies
  - 11.2.2.1. Sclerotherapy
  - 11.2.2.2. Radiofrequency Ablation Therapy
  - 11.2.2.3. Laser Treatment
11.3. Market Value Forecast, by Disease Type, 2017-2031
- 11.3.1. Deep-vein Thrombophlebitis
- 11.3.2. Varicose Veins
- 11.3.3. Superficial Thrombophlebitis
- 11.3.4. Chronic Venous Insufficiency
- 11.3.5. Venous Ulcers
- 11.3.6. Others
11.4. Market Value Forecast, by Product Type, 2017-2031
- 11.4.1. Ablation Devices
- 11.4.2. Venous Stents
- 11.4.3. Venous Closure Treatments
- 11.4.4. Sclerotherapy Injection
- 11.4.5. Others
11.5. Market Value Forecast, by End-user, 2017-2031
- 11.5.1. Hospitals
- 11.5.2. Clinics
- 11.5.3. Ambulatory centers
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. U.S.
- 11.6.2. Canada
11.7. Market Attractiveness Analysis
- 11.7.1. By Treatment
- 11.7.2. By Disease Type
- 11.7.3. By Product Type
- 11.7.4. By End-user
- 11.7.5. By Country/Sub-region

12. Europe Venous Diseases Treatment Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017-2031
- 12.2.1. Surgeries
  - 12.2.1.1. Angioplasty or Stenting
  - 12.2.1.2. Vein Ligation and Stripping
  - 12.2.1.3. VeEnd Use Cava Filter
  - 12.2.1.4. Ambulatory Phlebectomy
  - 12.2.1.5. Others
- 12.2.2. Therapies
  - 12.2.2.1. Sclerotherapy
  - 12.2.2.2. Radiofrequency Ablation Therapy
  - 12.2.2.3. Laser Treatment
12.3. Market Value Forecast, by Disease Type, 2017-2031
- 12.3.1. Deep-vein Thrombophlebitis
- 12.3.2. Varicose Veins
- 12.3.3. Superficial Thrombophlebitis
- 12.3.4. Chronic Venous Insufficiency
- 12.3.5. Venous Ulcers
- 12.3.6. Others
12.4. Market Value Forecast, by Product Type, 2017-2031
- 12.4.1. Ablation Devices
- 12.4.2. Venous Stents
- 12.4.3. Venous Closure Treatments
- 12.4.4. Sclerotherapy Injection
- 12.4.5. Others
12.5. Market Value Forecast, by End-user, 2017-2031
- 12.5.1. Hospitals
- 12.5.2. Clinics
- 12.5.3. Ambulatory centers
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
12.7. Market Attractiveness Analysis
- 12.7.1. By Treatment
- 12.7.2. By Disease Type
- 12.7.3. By Product Type
- 12.7.4. By End-user
- 12.7.5. By Country/Sub-region

13. Asia Pacific Venous Diseases Treatment Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017-2031
- 13.2.1. Surgeries
  - 13.2.1.1. Angioplasty or Stenting
  - 13.2.1.2. Vein Ligation and Stripping
  - 13.2.1.3. VeEnd Use Cava Filter
  - 13.2.1.4. Ambulatory Phlebectomy
  - 13.2.1.5. Others
- 13.2.2. Therapies
  - 13.2.2.1. Sclerotherapy
  - 13.2.2.2. Radiofrequency Ablation Therapy
  - 13.2.2.3. Laser Treatment
13.3. Market Value Forecast, by Disease Type, 2017-2031
- 13.3.1. Deep-vein Thrombophlebitis
- 13.3.2. Varicose Veins
- 13.3.3. Superficial Thrombophlebitis
- 13.3.4. Chronic Venous Insufficiency
- 13.3.5. Venous Ulcers
- 13.3.6. Others
13.4. Market Value Forecast, by Product Type, 2017-2031
- 13.4.1. Ablation Devices
- 13.4.2. Venous Stents
- 13.4.3. Venous Closure Treatments
- 13.4.4. Sclerotherapy Injection
- 13.4.5. Others
13.5. Market Value Forecast, by End-user, 2017-2031
- 13.5.1. Hospitals
- 13.5.2. Clinics
- 13.5.3. Ambulatory centers
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
- 13.7.1. By Treatment
- 13.7.2. By Disease Type
- 13.7.3. By Product Type
- 13.7.4. By End-user
- 13.7.5. By Country/Sub-region

14. Latin America Venous Diseases Treatment Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2017-2031
- 14.2.1. Surgeries
  - 14.2.1.1. Angioplasty or Stenting
  - 14.2.1.2. Vein Ligation and Stripping
  - 14.2.1.3. VeEnd Use Cava Filter
  - 14.2.1.4. Ambulatory Phlebectomy
  - 14.2.1.5. Others
- 14.2.2. Therapies
  - 14.2.2.1. Sclerotherapy
  - 14.2.2.2. Radiofrequency Ablation Therapy
  - 14.2.2.3. Laser Treatment
14.3. Market Value Forecast, by Disease Type, 2017-2031
- 14.3.1. Deep-vein Thrombophlebitis
- 14.3.2. Varicose Veins
- 14.3.3. Superficial Thrombophlebitis
- 14.3.4. Chronic Venous Insufficiency
- 14.3.5. Venous Ulcers
- 14.3.6. Others
14.4. Market Value Forecast, by Product Type, 2017-2031
- 14.4.1. Ablation Devices
- 14.4.2. Venous Stents
- 14.4.3. Venous Closure Treatments
- 14.4.4. Sclerotherapy Injection
- 14.4.5. Others
14.5. Market Value Forecast, by End-user, 2017-2031
- 14.5.1. Hospitals
- 14.5.2. Clinics
- 14.5.3. Ambulatory centers
14.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
- 14.7.1. By Treatment
- 14.7.2. By Disease Type
- 14.7.3. By Product Type
- 14.7.4. By End-user
- 14.7.5. By Country/Sub-region

15. Middle East & Africa Venous Diseases Treatment Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment, 2017-2031
- 15.2.1. Surgeries
  - 15.2.1.1. Angioplasty or Stenting
  - 15.2.1.2. Vein Ligation and Stripping
  - 15.2.1.3. VeEnd Use Cava Filter
  - 15.2.1.4. Ambulatory Phlebectomy
  - 15.2.1.5. Others
- 15.2.2. Therapies
  - 15.2.2.1. Sclerotherapy
  - 15.2.2.2. Radiofrequency Ablation Therapy
  - 15.2.2.3. Laser Treatment
15.3. Market Value Forecast, by Disease Type, 2017-2031
- 15.3.1. Deep-vein Thrombophlebitis
- 15.3.2. Varicose Veins
- 15.3.3. Superficial Thrombophlebitis
- 15.3.4. Chronic Venous Insufficiency
- 15.3.5. Venous Ulcers
- 15.3.6. Others
15.4. Market Value Forecast, by Product Type, 2017-2031
- 15.4.1. Ablation Devices
- 15.4.2. Venous Stents
- 15.4.3. Venous Closure Treatments
- 15.4.4. Sclerotherapy Injection
- 15.4.5. Others
15.5. Market Value Forecast, by End-user, 2017-2031
- 15.5.1. Hospitals
- 15.5.2. Clinics
- 15.5.3. Ambulatory centers
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

16. Competitive Landscape

16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
- 16.3.1. Zimmer Biomet Holdings, Inc.
  - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.1.2. Company Financials
  - 16.3.1.3. Growth Strategies
  - 16.3.1.4. SWOT Analysis
- 16.3.2. Medtronic
  - 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.2.2. Company Financials
  - 16.3.2.3. Growth Strategies
  - 16.3.2.4. SWOT Analysis
- 16.3.3. AngioDynamics
  - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.3.2. Company Financials
  - 16.3.3.3. Growth Strategies
  - 16.3.3.4. SWOT Analysis
- 16.3.4. Alma Lasers
  - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.4.2. Company Financials
  - 16.3.4.3. Growth Strategies
  - 16.3.4.4. SWOT Analysis
- 16.3.5. Biolitec AG Untere Viaduktgasse
  - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.5.2. Company Financials
  - 16.3.5.3. Growth Strategies
  - 16.3.5.4. SWOT Analysis
- 16.3.6. Becton, Dickinson and Company
  - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.6.2. Company Financials
  - 16.3.6.3. Growth Strategies
  - 16.3.6.4. SWOT Analysis
- 16.3.7. Boston Scientific Corporation
  - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.7.2. Company Financials
  - 16.3.7.3. Growth Strategies
  - 16.3.7.4. SWOT Analysis
- 16.3.8. Abbott Laboratories
  - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.8.2. Company Financials
  - 16.3.8.3. Growth Strategies
  - 16.3.8.4. SWOT Analysis
- 16.3.9. B. Braun Melsungen AG
  - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.9.2. Company Financials
  - 16.3.9.3. Growth Strategies
  - 16.3.9.4. SWOT Analysis
- 16.3.10. Teleflex Incorporated
  - 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.10.2. Company Financials
  - 16.3.10.3. Growth Strategies
  - 16.3.10.4. SWOT Analysis
- 16.3.11. Lumenis
  - 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.11.2. Company Financials
  - 16.3.11.3. Growth Strategies
  - 16.3.11.4. SWOT Analysis
- 16.3.12. Philips
  - 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.12.2. Company Financials
  - 16.3.12.3. Growth Strategies
  - 16.3.12.4. SWOT Analysis

静脈疾患治療の世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Venous Diseases Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts, 2022-2031

目次

第1章序文

第2章前提条件と調査手法

第3章エグゼクティブサマリー：世界の静脈疾患治療市場

第4章市場概要

第5章主要洞察

第6章世界の静脈疾患治療の分析と予測：治療タイプ別

第7章世界の静脈疾患治療の分析と予測：疾患タイプ別

第8章世界の静脈疾患治療の分析と予測：製品タイプ別

第9章世界の静脈疾患治療の分析と予測：エンドユーザー別

第10章世界の静脈疾患治療の分析と予測：地域別

第11章北米の静脈疾患治療の分析と予測

第12章欧州の静脈疾患治療の分析と予測

第13章アジア太平洋の静脈疾患治療の分析と予測

第14章ラテンアメリカの静脈疾患治療の分析と予測

第15章中東・アフリカの静脈疾患治療の分析と予測

第16章競合情勢

List of Tables

List of Figures

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Venous Diseases Treatment Market

4. Market Overview

5. Key Insights

6. Global Venous Diseases Treatment Analysis and Forecast, by Treatment Type

7. Global Venous Diseases Treatment Analysis and Forecast, by Disease Type

8. Global Venous Diseases Treatment Analysis and Forecast, by Product Type

9. Global Venous Diseases Treatment Analysis and Forecast, by End-user

10. Global Venous Diseases Treatment Analysis and Forecast, by Region

11. North America Venous Diseases Treatment Analysis and Forecast

12. Europe Venous Diseases Treatment Analysis and Forecast

13. Asia Pacific Venous Diseases Treatment Analysis and Forecast

14. Latin America Venous Diseases Treatment Analysis and Forecast

15. Middle East & Africa Venous Diseases Treatment Analysis and Forecast

16. Competitive Landscape

静脈疾患治療の世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Venous Diseases Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts, 2022-2031

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界の静脈疾患治療市場

第4章 市場概要

第5章 主要洞察

第6章 世界の静脈疾患治療の分析と予測：治療タイプ別

第7章 世界の静脈疾患治療の分析と予測：疾患タイプ別

第8章 世界の静脈疾患治療の分析と予測：製品タイプ別

第9章 世界の静脈疾患治療の分析と予測：エンドユーザー別

第10章 世界の静脈疾患治療の分析と予測：地域別

第11章 北米の静脈疾患治療の分析と予測

第12章 欧州の静脈疾患治療の分析と予測

第13章 アジア太平洋の静脈疾患治療の分析と予測

第14章 ラテンアメリカの静脈疾患治療の分析と予測

第15章 中東・アフリカの静脈疾患治療の分析と予測

第16章 競合情勢

List of Tables

List of Figures

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Venous Diseases Treatment Market

4. Market Overview

5. Key Insights

6. Global Venous Diseases Treatment Analysis and Forecast, by Treatment Type

7. Global Venous Diseases Treatment Analysis and Forecast, by Disease Type

8. Global Venous Diseases Treatment Analysis and Forecast, by Product Type

9. Global Venous Diseases Treatment Analysis and Forecast, by End-user

10. Global Venous Diseases Treatment Analysis and Forecast, by Region

11. North America Venous Diseases Treatment Analysis and Forecast

12. Europe Venous Diseases Treatment Analysis and Forecast

13. Asia Pacific Venous Diseases Treatment Analysis and Forecast

14. Latin America Venous Diseases Treatment Analysis and Forecast

15. Middle East & Africa Venous Diseases Treatment Analysis and Forecast

16. Competitive Landscape

第1章序文

第2章前提条件と調査手法

第3章エグゼクティブサマリー：世界の静脈疾患治療市場

第4章市場概要

第5章主要洞察

第6章世界の静脈疾患治療の分析と予測：治療タイプ別

第7章世界の静脈疾患治療の分析と予測：疾患タイプ別

第8章世界の静脈疾患治療の分析と予測：製品タイプ別

第9章世界の静脈疾患治療の分析と予測：エンドユーザー別

第10章世界の静脈疾患治療の分析と予測：地域別

第11章北米の静脈疾患治療の分析と予測

第12章欧州の静脈疾患治療の分析と予測

第13章アジア太平洋の静脈疾患治療の分析と予測

第14章ラテンアメリカの静脈疾患治療の分析と予測

第15章中東・アフリカの静脈疾患治療の分析と予測

第16章競合情勢